Anlon Healthcare Limited has officially announced a significant strategic move following its Board Meeting held on April 16, 2026. The company has approved the acquisition of a 63.98% stake in Remember India Health Links Private Limited, a move that will transform the target entity into a subsidiary of Anlon Healthcare. This acquisition involves the purchase of 1.11 crore equity shares for a total cash consideration of approximately ₹5.38 Crores.

The acquisition is structured as a cash deal and is expected to be finalized within 4 to 5 months, subject to standard closing conditions. Through this transaction, Anlon Healthcare aims to evolve from a specialized Active Pharmaceutical Ingredient (API) manufacturer into a comprehensive pharmaceutical provider. By integrating Remember India Health Links, Anlon gains immediate access to over 30 dossiers for finished dosage formulations (FDFs), including tablets and capsules, allowing it to move further down the pharmaceutical value chain into retail and hospital markets.

Anlon Healthcare Limited, headquartered in Rajkot, Gujarat, is deeply entrenched in the pharmaceutical sector, traditionally focusing on the production of high-quality drug substances. Throughout 2025, the company remained focused on strengthening its domestic and international market positioning. Recent updates highlight the company’s shift toward a B2B and B2C hybrid model, leveraging its manufacturing capabilities to enter broader healthcare platforms. The target company, Remember India Health Links, reported a turnover of ₹0.83 Crores for the financial year ending March 31, 2025, following previous years of ₹1.70 Crores (2023-24) and ₹0.99 Crores (2022-23).

Regarding financial performance, Anlon Healthcare has been actively monitoring its growth trajectory throughout the 2025 calendar year. While the current notice focuses on the acquisition outcome rather than the full quarterly financial tables, the company has previously engaged in rigorous reporting of its 2025 corporate financial data to maintain transparency with stakeholders. In the broader context of 2025, the pharmaceutical industry saw significant shifts in supply chain dynamics, and Anlon’s move to secure finished dosage capabilities is a direct response to these market trends. The company continues to be led by Managing Director Punitkumar Rasadia, who has overseen the firm’s transition through recent regulatory and expansionary phases.